A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia.
Gabrielle S Sellick, Lynn R Goldin, Ruth W Wild...
https://pubmed.ncbi.nlm.nih.gov/17687107Actively Recruiting
Age: 18Years - 100Years
All Genders
Healthy Volunteers
ID00626496
Genetic Epidemiology of Lymphoproliferative Disorders
Led by Mayo Clinic · Updated on 2025-10-14
3000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
M
Mayo Clinic
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying blood and lymph node cancers, which include lymphoma, leukemia, and myeloma. These cancers involve uncontrolled growth of white blood cells and have many subtypes such as chronic lymphocytic leukemia and non-Hodgkin lymphoma. The study aims to understand how genetics and environmental factors contribute to the development of these cancers, especially since they tend to occur in families. This is an observational study conducted by the Mayo Clinic, focusing on families with multiple members affected by lymphoproliferative disorders. There are no treatments or interventions being tested. Instead, the study collects information to assess the risk of developing blood or lymphoma cancers over time. Participants will be observed for ongoing risk related to blood and lymphoma cancers. The study involves gathering family history and possibly other data to better understand genetic and environmental contributions. Individuals may be followed long term to monitor cancer risks, with no active treatment or procedures involved in the trial.
CONDITIONS
Brief Title
Family Study of Lymphoproliferative Disorders
Who Can Participate
Age: 18Years - 100Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- At least 2 living, blood related relatives, affected with a lymphoproliferative disorder.
You will not qualify if you...
- None specified.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Monitoring
Duration - Up to 10 years
Participants are observed to assess the risk of blood or lymphoma over time.
Periodic visits as determined by the study team
Trial Site Locations
Total: 1 location
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
Actively Recruiting
Loading map...
Research Team
C
Catie Erding
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Susceptibility genes and B-chronic lymphocytic leukaemia.
Susan L Slager, Neil E Kay, Zachary S Fredericksen...
https://pubmed.ncbi.nlm.nih.gov/18021089Chronic lymphocytic leukaemia genetics overview.
Neil Caporaso, Lynn Goldin, Christoph Plass...
https://pubmed.ncbi.nlm.nih.gov/18021078Familial CLL: genes and environment.
Lynn R Goldin, Susan L Slager
https://pubmed.ncbi.nlm.nih.gov/18024649Familial chronic lymphocytic leukemia: what does it mean to me?
Susan L Slager, Neil E Kay
https://pubmed.ncbi.nlm.nih.gov/19778840Genetic susceptibility variants for chronic lymphocytic leukemia.
Susan L Slager, Lynn R Goldin, Sara S Strom...
https://pubmed.ncbi.nlm.nih.gov/20332261Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32.
Lucia Conde, Eran Halperin, Nicholas K Akers...
https://pubmed.ncbi.nlm.nih.gov/20639881Familial chronic lymphocytic leukemia.
Lynn R Goldin, Susan L Slager, Neil E Caporaso
https://pubmed.ncbi.nlm.nih.gov/20389242Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families.
Lynn R Goldin, Mark C Lanasa, Susan L Slager...
https://pubmed.ncbi.nlm.nih.gov/20738309Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL.
Susan L Slager, Kari G Rabe, Sara J Achenbach...
https://pubmed.ncbi.nlm.nih.gov/21131588